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SIRS, We thank Maratea et al. for their insightful com-
ments.1 Network meta-analyses (NMAs) are becoming
increasingly common in the medical literature. Various
analytic techniques are available for NMAs. In our
study,2 we used a Bayesian-driven approach with unin-
formed priors and found only nonsigniﬁcant trends
when comparing anti-tumour necrosis factor (TNF)
agents for both remission and response.
We agree that it is important to differentiate between
“no proof of difference” (i.e., an inconclusive result) and
“proof of no difference” (i.e., equivalence) and ﬁnd the
results by Maratea and colleagues interesting. However,
as the authors point out, their conclusions are based on
an underlying assumption (margin of 12%), which has a
“certain degree of arbitrariness”.
Thus, despite its sophistication, even this approach is
also inherently inconclusive regarding deﬁnite superiority
or equivalence among anti-TNF agents. Until more con-
clusive data are available, we believe that other factors
such as preference, safety, cost and route of administra-
tion should dictate choice of anti-TNF agents. Ultimately,
a randomised controlled trial among anti-TNF agents in
UC is of practical size and should be performed.
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SIRS, We read with interest the review by Moran and col-
leagues on dermatological complications of immunosup-
pressive therapies for inﬂammatory bowel disease (IBD),
particularly anti-tumour necrosis factor alpha (TNFa)-in-
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